INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets [Table Text Block]

The value of the Company’s intangible assets including gross asset value and carrying value is summarized below ($ in thousands):

					Human		Anti-ferritin
	Bertilimumab		NanomAbs		Antibodies		Antibody
	iCo		Yissum		Kadouche		MabLife		Total
Balance as of December 31, 2013	$	2,087	$	567	$	568	$	385	$	3,607
Addition		-		-		-		111		111
Amortization		(167)		(46)		(47)		(43)		(303)
Balance, December 31, 2014		1,920		521		521		453		3,415
Additions		-		-		-
Amortization		(167)		(46)		(46)		(45)		(304)
Balance, December 31, 2015	$	1,753	$	475	$	475	$	408	$	3,111
Gross asset value	$	2,509	$	694	$	700	$	547	$	4,450
Accumulated amortization		(756)		(219)		(225)		(139)		(1,339)
Carrying value December 31, 2015	$	1,753	$	475	$	475	$	408	$	3,111

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]

Estimated amortization expense for each of the five succeeding years, based upon the Company’s intangible assets owned at December 31, 2015 is as follows ($ in thousands):

Period Ending December 31,	Amount
2016	$	305
2017		305
2018		305
2019		305
2020		305
2021 and thereafter		1,586
Total	$	3,111